 Connection
Ross Kedl to Cell Line, Tumor
This is a "connection" page, showing publications Ross Kedl has written about Cell Line, Tumor.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
0.092 |
|
|
|
-
McWilliams JA, McGurran SM, Dow SW, Slansky JE, Kedl RM. A modified tyrosinase-related protein 2 epitope generates high-affinity tumor-specific T cells but does not mediate therapeutic efficacy in an intradermal tumor model. J Immunol. 2006 Jul 01; 177(1):155-61.
Score: 0.038
-
DeGolier KR, Danis E, D'Antonio M, Cimons J, Yarnell M, Kedl RM, Kohler ME, Scott-Browne JP, Fry TJ. Antigen experience history directs distinct functional states of CD8+ CAR T cells during the antileukemia response. Nat Immunol. 2025 Jan; 26(1):68-81.
Score: 0.034
-
Ahonen CL, Wasiuk A, Fuse S, Turk MJ, Ernstoff MS, Suriawinata AA, Gorham JD, Kedl RM, Usherwood EJ, Noelle RJ. Enhanced efficacy and reduced toxicity of multifactorial adjuvants compared with unitary adjuvants as cancer vaccines. Blood. 2008 Mar 15; 111(6):3116-25.
Score: 0.011
-
U'Ren L, Kedl R, Dow S. Vaccination with liposome--DNA complexes elicits enhanced antitumor immunity. Cancer Gene Ther. 2006 Nov; 13(11):1033-44.
Score: 0.010
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|